News An aura of adult migraine hope as NICE recommends Vyepti Lundbeck’s eptinezumab receives NICE recommendation for the prevention of migraine in adults.
News Amid crowded migraine market, Lundbeck goes its own way The market for migraine treatment and prevention has been transformed by the launch of several new drugs targeting CGRP for many sufferers, but Lundbeck thinks there is still room for new a
News FDA approves 'potential blockbuster' migraine jab from Lundb... The FDA has approved Lundbeck’s eptinezumab prophylactic treatment for migraine, the last from a gang of four drugs from a new class.
News Angelini Pharma's R&D chief heads for the exit Dr Rafal Kaminski's near five-year tenure as chief scientific officer of Italy's Angelini Pharma will come to an end in the next couple of weeks.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.